Novo Nordisk announced that its drug Mim8 showed a 97% and 99% reduction in treated bleeding episodes for weekly and monthly doses respectively, in a clinical trial involving 254 people with hemophilia A, on May 13, 2024. It plans to seek regulatory approval for Mim8 by the end of 2024.